CIPLA1,374.00

Cipla Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYLUPINAPOLLOHOSPMAXHEALTHDIVISLABTORNTPHARMZYDUSLIFEMcap ₹1.11L Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity15.3816.8511.2411.24
Return on Assets12.7014.099.099.09
Return on Capital Employed19.0718.8713.1713.17
Return on Invested Capital17.6819.8713.2711.48
Margins
EBITDA Margin24.4125.8720.8918.70
Operating Margin20.3321.8616.5916.59
Incremental Operating Margin44.03-219.37
Pretax Margin22.1224.7618.5516.01
Net Income Margin16.1219.1313.7111.85
Net Income to Common Margin15.9919.1413.7711.90
FCF Margin10.8012.553.063.06
Additional
Effective Tax Rate27.1222.4325.9225.81
Dvd Payout Ratio16.5219.9233.47
Sustainable Growth Rate12.8413.497.4811.24
Incremental Operating Margin %44.03-219.37-393.89
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 146%.